• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Definitive Healthcare Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    2/27/25 4:12:20 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology
    Get the next $DH alert in real time by email
    8-K
    0001861795false00018617952025-02-242025-02-24

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):

    February 24, 2025

     

    Definitive Healthcare Corp.

    (Exact name of Registrant as Specified in Its Charter)

    Commission File Number 001-40815

     

     

     

    Delaware

     

    86-3988281

    (State
    of Incorporation)

     

    (IRS Employer
    Identification No.)

     

    492 Old Connecticut Path, Suite 401

     

     

    Framingham, Massachusetts 01701

     

     

    (Address of Principal Executive Offices)

     

    508 720-4224

    Registrant’s telephone number, including area code

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of Each Class

    Trading
    Symbol

    Name of Each Exchange on Which Registered

    Class A Common Stock, $0.001 par value

    DH

    The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



     

    Item 2.02 Results of Operations and Financial Condition.

    On February 27, 2025, Definitive Healthcare Corp. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

    The information furnished in this Item 2.02 on this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, regardless of any general incorporation language in such filing.

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On February 24, 2025, the Board of Directors (the “Board”) of the Company appointed Casey Heller to the position of Chief Financial Officer (“CFO”) effective June 2, 2025. The Company previously announced that Richard Booth, the Company’s current CFO, would be departing the Company effective June 1, 2025.

    Ms. Heller, age 36, currently serves as the Company’s SVP of Finance, a role she has occupied since October 2024, having previously served as the Company’s VP of FP&A from January 2024 to October 2024. Before joining the Company, Ms. Heller spent 15 years in Finance at IBM between July 2009 and December 2023, holding progressive leadership roles across broad financial disciplines, including serving as VP of Investor Relations from August 2023 to December 2023, Director of Investor Relations from February 2022 to August 2023, and Director of Treasury Strategy from June 2019 to March 2022. During her time at IBM, Ms. Heller also served as the Chief of Staff to IBM’s CFO, led FP&A for the software business, was responsible for overall IBM forecasting, and was selected to help support strategic transactions, including the spin-off of IBM’s managed infrastructure services businesses and deleveraging after the Red Hat acquisition. Ms. Heller holds a B.S. in Business Administration with a concentration in Finance from Marist College.

    Heller Promotion Offer Letter

    In connection with Ms. Heller’s appointment as CFO, the Company entered into a promotion offer letter with Ms. Heller, dated as of February 24, 2025 (the “Offer Letter”). Pursuant to the terms of the Offer Letter, Ms. Heller is entitled to, among other things, in each case effective as of June 2, 2025, (i) an initial annual base salary of $375,000, (ii) a target bonus opportunity of 60% of her base salary, subject to the Company’s Cash Incentive Plan for Executives, to be pro-rated to account for base salary and bonus opportunity applicable during 2025, (iii) certain severance benefits as offset forth in the Offer Letter, (iv) an award of time-vesting restricted stock units (“RSUs”) (the “Initial Promotion RSUs”) with respect to the Company’s Class A Common Stock, par value $0.001 per share (the “Class A Common Stock”), and (v) an award of RSUs (the “Annual RSUs”) and performance-based restricted stock units (“PSUs”) (the “Annual PSUs”) consistent with annual equity awards issued to similarly-situated executives of the Company (together, the “Initial Annual Awards”). The Initial Promotion RSUs and the Initial Annual Awards will all be issued pursuant to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”).

    The Initial Promotion RSUs will have a target value at grant of $1,500,000, and the number of RSUs subject to the Initial Promotion RSUs will be determined by dividing such grant value by the average closing price of a share of Common Stock for the thirty (30) trading days preceding (but not including) June 2, 2025, rounded up to the nearest whole share. The RSUs subject to the Initial Promotion RSUs will vest over two years with the first vest of 50% occurring on the first of the month on which the 1-year anniversary of the CFO start date falls (i.e., June 1, 2026), with the remaining shares vesting quarterly in approximately equal installments thereafter.

    The Annual RSUs will have a target value at grant of $1,462,500 and the Annual PSUs will have a target value at grant of $787,500. The actual number of RSUs or PSUs (at target), as applicable, subject to the Initial Annual Awards, will be determined by dividing such estimated value by the average closing price of a share of Common Stock for the thirty (30) trading days preceding (but not including) the date of grant, rounded up to the nearest whole share. The Initial Annual Awards will be granted to Ms. Heller on the later of (a) the date on which 2025 annual equity awards are granted to other similarly situated executives; and (b) a date that is on or promptly following June 2, 2025. The Annual RSUs will vest over a four-year period with 25% vesting after 1 year and then quarterly vesting thereafter over the remaining 3 years. The Annual PSUs will be subject to, and will vest in accordance with, the terms of 2025 annual performance-based equity awards established by the Board or the Human Capital Management & Compensation Committee of the Board for issuance to other similarly-situated executive officers of the Company.


    Pursuant to Ms. Heller’s Offer Letter, she is entitled to certain severance benefits, as provided by the Company’s Severance Plan for Executives (Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on November 21, 2023), as modified by the terms of the Offer Letter, and the Company’s Change in Control Severance Plan for Executives (Exhibit 10.36 to the Company's Annual Report on Form 10-K (File No. 001-40815) filed with the SEC on February 27, 2023).

    If we terminate Ms. Heller’s employment without cause (as defined in the Offer Letter) and other than as a result of death or disability, or Ms. Heller terminates his employment for good reason (as defined in the Offer Letter) then we must provide Ms. Heller with (i) continuation of regular payments of salary at the rate in effect on the date of termination for a period of twelve months from the date of termination of employment, payable in accordance with our regular payroll schedule; (ii) payment of any unpaid amount of the annual bonus for the immediately preceding calendar year that Ms. Heller would have earned in accordance with the Bonus Plan had the termination not occurred, plus an amount equal to the target annual bonus to be earned by Ms. Heller during the year in which the termination occurs, payable in a lump sum; (iii) acceleration of the vesting of all forms of time-based equity awarded to Ms. Heller by the Company at any time, that would otherwise have vested during the twelve-month period following the termination date, and (iv) payment for twelve months of COBRA coverage, if applicable.

    Ms. Heller is eligible for reimbursement of certain expenses and will be entitled to participate in the Company’s benefit plans that are generally available to the Company’s executive employees. Ms. Heller’s Offer Letter also entitles her to payment of up to $10,000 in legal fees in connection with the negotiation of her Offer Letter. Ms. Heller will also enter into the Company’s standard form of indemnity agreement in the form previously approved by the Board, which form is filed as Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021.

    The foregoing summary is not a complete description and is qualified in its entirety by reference to the full text and terms of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    10.1

    Offer Letter, dated February 24, 2025, by and among Casey Heller, Definitive Healthcare Corp. and Definitive Healthcare, LLC.

    99.1

    Press Release Dated February 27, 2025 (furnished herewith pursuant to Item 2.02)

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    DEFINITIVE HEALTHCARE CORP.

     

     

     

    By:

    /s/ Richard Booth

     

    Name:

    Richard Booth

     

    Title:

    Chief Financial Officer

     

     

     

     

    Date: February 27, 2025

     


    Get the next $DH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DH

    DatePrice TargetRatingAnalyst
    1/13/2025$4.00Equal Weight → Underweight
    Barclays
    12/20/2024$5.00Equal-Weight
    Stephens
    9/17/2024$7.00Buy
    BTIG Research
    7/31/2024$7.00 → $5.00Neutral → Underweight
    JP Morgan
    5/8/2024$11.50 → $9.00Overweight → Equal-Weight
    Morgan Stanley
    1/17/2024Buy → Hold
    Needham
    1/5/2024Buy → Hold
    Canaccord Genuity
    7/24/2023$13.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $DH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Booth Richard Douglas covered exercise/tax liability with 7,873 shares, decreasing direct ownership by 1% to 652,630 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:10 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • EXECUTIVE CHAIRMAN Krantz Jason Ronald covered exercise/tax liability with 18,795 shares, decreasing direct ownership by 2% to 1,106,362 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:14 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • CHIEF OPERATING OFFICER Shamsuddin Kate Marie covered exercise/tax liability with 4,595 shares, decreasing direct ownership by 0.65% to 699,902 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:11 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Definitive Healthcare Corp.

      10-Q - Definitive Healthcare Corp. (0001861795) (Filer)

      5/8/25 4:22:09 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Definitive Healthcare Corp. (0001861795) (Filer)

      5/8/25 4:10:28 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form DEFA14A filed by Definitive Healthcare Corp.

      DEFA14A - Definitive Healthcare Corp. (0001861795) (Filer)

      4/23/25 4:17:22 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Financials

    Live finance-specific insights

    See more

    $DH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

      FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025.  First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024.  Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024.   Adjusted EBITDA was $14.7 million, or 25% of revenue, compar

      5/8/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast

      FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

      4/24/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024

      FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023.  Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023.   Adjusted EBITDA was $17.5 million, or 28%

      2/27/25 4:05:53 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

      FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025.  First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024.  Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024.   Adjusted EBITDA was $14.7 million, or 25% of revenue, compar

      5/8/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast

      FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

      4/24/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

      FRAMINGHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the "Committee") of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Jeff Moyer, Definitive Healthcare's new SVP of Growth and Sales Operations, an inducement award consisting of 364,432 time-based restricted stock units ("RSUs"), effective April 3, 2025. These awards were individually negotiated and granted as an inducement material to Mr. Moyer's respective commencement of

      4/4/25 8:00:00 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Definitive Healthcare Corp.

      SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      11/12/24 11:54:03 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Definitive Healthcare Corp.

      SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      10/3/24 9:08:57 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Definitive Healthcare Corp. (Amendment)

      SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)

      2/14/24 4:00:33 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Definitive Healthcare downgraded by Barclays with a new price target

      Barclays downgraded Definitive Healthcare from Equal Weight to Underweight and set a new price target of $4.00

      1/13/25 7:41:23 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Stephens initiated coverage on Definitive Healthcare with a new price target

      Stephens initiated coverage of Definitive Healthcare with a rating of Equal-Weight and set a new price target of $5.00

      12/20/24 7:31:03 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • BTIG Research initiated coverage on Definitive Healthcare with a new price target

      BTIG Research initiated coverage of Definitive Healthcare with a rating of Buy and set a new price target of $7.00

      9/17/24 7:25:14 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Leadership Updates

    Live Leadership Updates

    See more
    • Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth

      FRAMINGHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. "Kevin is an outstanding leader. He has deep, hands-on experience with data-focused businesses and has a

      5/28/24 8:00:00 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Established Executive and Milwaukee Business Leader Jim Emling Joins VBA as Executive Chair of the Board of Directors

      Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv

      11/28/23 5:00:00 PM ET
      $DH
      $GDRX
      Computer Software: Prepackaged Software
      Technology
      EDP Services
    • Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

      FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. "I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new Chief Revenue Officer," said Robert Musslewhite, Chief Executive Officer of Definitive Healthcare. "Carrie is a fantastic fit for Definitive Healthcare. Her values and her deep belief in the power of humble collaboration make her a perfect match for our culture. Carrie brings a wealth of experience selling Software as a Service to both enterprise accounts and

      10/5/23 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology